Nestmedic SA
0.63
PLN
+0.00
(-0.63%)
ISIN
PLNSTMD00010
Return %
Stock
S&P 500
1Y
-26.55
14.20
3Y
-53.13
81.12
5Y
-50.75
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jacek Marek Gnich
- Full Time Employees
- 3
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Warsaw Poland
- IPO Date
- Jun 12, 2017
- Website
- nestmedic.com
- Similar Companies
- Business
- Nestmedic S.A. is a Poland-based medical technology company that specializes in the design, manufacture, and commercialization of telemedical solutions for fetal and maternal monitoring in obstetrics and gynecology. The company offers integrated digital health systems comprising the Pregnabit and Pregnabit Pro mobile cardiotocography (teleCTG) diagnostic devices, which record fetal heart rate, maternal pulse, and uterine contractions with wireless data transmission; the Pregnabit Cloud telemedical platform, a secure digital infrastructure for transmitting, storing, and analyzing diagnostic CTG examination data; a proprietary Medical Telemonitoring Center service, providing 24/7 continuous professional medical analysis and trace interpretation for expectant mothers; and the PregnaOne system, an advanced diagnostic device engineered for home and clinical prenatal monitoring. Nestmedic S.A. serves hospitals, prenatal and obstetric clinics, private healthcare practices, midwives, and pregnant patients across institutional healthcare, outpatient, and remote care environments. The company operates internationally through direct sales and specialized medical distributor networks across Poland, the Czech Republic, Slovakia, Norway, Denmark, and Israel, while actively expanding into the North American market. Founded in 2014, incorporated as a joint-stock company in 2017, and headquartered in Warsaw, Poland, Nestmedic S.A. is listed on the NewConnect market of the Warsaw Stock Exchange under the ticker symbol NST. Recent corporate developments include the completion of clinical validation studies in the United States and the formal submission and substantive review of a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) for the PregnaOne teleCTG system; the execution of multi-year international distribution agreements with ScanMed A/S for Norway and Denmark and Medlife LTD for Israel to expand its global commercial footprint alongside existing partnership arrangements with Synektik; and the registration of Series Z share capital increases to finance global market access, regulatory compliance, and continuous product development.